2024
Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017
Marczyk M, Kahn A, Silber A, Rosenblit M, Digiovanna M, Lustberg M, Pusztai L. Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017. Journal Of The National Cancer Institute 2024, djae241. PMID: 39348186, DOI: 10.1093/jnci/djae241.Peer-Reviewed Original ResearchBreast cancer-specific deathCancer-specific deathBreast cancerStage IAll-cause mortalityTemporal trendsStage I/II breast cancerHormone receptor-positiveNode-negative cancersPrimary tumor typeStage I/II diseaseMetastatic breast cancerStage II cancerBilateral cancerIV cancerFemale sexIV diseaseReceptor-positiveExcellent prognosisII cancerClinical stageTumor typesTreated patientsStage IIICancer
2013
Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study.
Sinclair N, Sakr B, Abu-Khalaf M, Somlo G, Black R, Chung G, Rizack T, Strenger R, Fenton M, DiGiovanna M, Constantinou M, Lannin D, Legare R, Chagpar A, Sambandam S, Bossuyt V, Rosati K, Harris L, Sikov W. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study. Journal Of Clinical Oncology 2013, 31: 619-619. DOI: 10.1200/jco.2013.31.15_suppl.619.Peer-Reviewed Original ResearchPathologic complete responseResidual cancer burdenNeoadjuvant chemotherapyT regimenNab-paclitaxelBreast cancerMulticenter phase II trialHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Median age 51Weekly nab-paclitaxelPhase II trialGrowth factor receptor 2Factor receptor 2Adjuvant chemotherapyFebrile neutropeniaNeoadjuvant carboplatinAdjuvant treatmentII trialDose intensityExcellent prognosisPathologic responseResearch biopsiesComplete responseResidual tumor